Astrana Health earnings release, May 7, 2026

Astrana Health, Inc. (ASTH) · Form 8-K, Item 2.02 · Filed · SEC filing

Astrana Health, Inc. Reports First Quarter

2026 Results

Company to Host Conference Call on Thursday,

May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET

ALHAMBRA, Calif.,

May 7, 2026

/PRNewswire/

-- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”)

(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2026.

“We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “In an increasingly dynamic healthcare environment, we believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time.”

Financial Highlights for First Quarter Ended March 31, 2026:

All comparisons are to the three months ended

March 31, 2025 unless otherwise stated.

(1)

See “Reconciliation of Net Income to EBITDA,

Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information.

(2)

See reconciliation provided with the condensed consolidated statements of cash flow and “Use of Non-GAAP Financial Measures” below for additional information.

(3)

See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.

Recent Operating Highlights

Segment Results for three months ended March 31,

2026:

All comparisons are to the three months ended

March 31, 2025 unless otherwise stated.

(1)

Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table.

2026 Guidance:

Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the quarter ending June 30, 2026 and reiterating guidance for the year ending December 31,

2026 based on the Company’s existing business, current view of existing market conditions, and assumptions.

Financial statements

Income Statement

Three Months Ended March 31, 2026 — All comparisons are to the three months ended March 31, 2025 unless otherwise stated. (in thousands)

Three Months Ended March 31, 2026 – Care PartnersThree Months Ended March 31, 2026 – Care DeliveryThree Months Ended March 31, 2026 – Care EnablementThree Months Ended March 31, 2026 – Intersegment EliminationThree Months Ended March 31, 2026Three Months Ended March 31, 2026 – Corporate CostsThree Months Ended March 31, 2026 – Consolidated Total
Total revenues909,70385,07787,745-117,425)$—965,100
% change vs. prior year quarter51.0%155.0%122.0%
Cost of services785,53172,54448,704-47,423)859,356
General and administrative expenses72,54614,37417,259-69,974)27,53261,737
Depreciation and amortization12,1701,1221,62955815,479
Total expenses870,24788,04067,592-117,397)28,090936,572
Income (loss) from operations39,456-2,96320,153-28-1-28,09028,528
% change vs. prior year quarter-11.0%-5.0%470.0%

Income Statement

Three Months Ending June 30, 2026 (in millions)

Three Months Ending June 30, 2026 – Guidance Range – LowThree Months Ending June 30, 2026 – Guidance Range – HighYear Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Total revenue9651,0003,8004,100
Adjusted EBITDA6570250280
Free cash flow105132.5

Income Statement

Three Months Ended March 31, — (UNAUDITED) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenueCapitation, net892,908583,963
RevenueRisk pool settlements and incentives12,48614,491
RevenueManagement fee income15,6852,310
RevenueFee-for-service, net37,83114,890
RevenueOther revenue6,1904,736
RevenueTotal revenue965,100620,390
Operating expensesCost of services, excluding depreciation and amortization859,356549,061
Operating expensesGeneral and administrative expenses61,73743,897
Operating expensesDepreciation and amortization15,4796,849
Operating expensesTotal expenses936,572599,807
Operating expensesIncome from operations28,52820,583
Other (expense) incomeIncome (loss) from equity method investments1,720-867
Other (expense) incomeInterest expense-16,101-7,308
Other (expense) incomeInterest income3,8162,312
Other (expense) incomeUnrealized gain (loss) on investments1,084-44
Other (expense) incomeOther income (loss)662-5,072
Other (expense) incomeTotal other expense, net-8,819-10,979
Other (expense) incomeIncome before provision for income taxes19,7099,604
Other (expense) incomeProvision for income taxes6,5783,383
Other (expense) incomeNet income13,1316,221
Other (expense) incomeNet loss attributable to non-controlling interests-1,305-471
Other (expense) incomeNet income attributable to Astrana Health, Inc.14,4366,692
Other (expense) incomeEarnings per share – basic0.30.14
Other (expense) incomeEarnings per share – diluted0.290.14
Other (expense) incomeWeighted average shares of common stock outstanding – basic48,853,67848,470,682
Other (expense) incomeWeighted average shares of common stock outstanding – diluted49,054,13548,850,666

Income Statement

Three Months Ended March 31, (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31,Three Months Ended March 31, – 2025
Net income13,1316,221
Interest expense16,1017,308
Interest income-3,816)-2,312)
Provision for income taxes6,5783,383
Depreciation and amortization15,4796,849
EBITDA47,47321,449
(Income) loss from equity method investments-1,720)867
Other, net10,650-16,259-2
Stock-based compensation9,8957,811
Adjusted EBITDA66,29836,386
Total revenue965,100620,390
Adjusted EBITDA margin7%6%

Income Statement

Three Months Ended March 31, (in thousands, except for share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31,Three Months Ended March 31, – 2025
Net income13,1316,221
(Income) loss from equity method investments-1,720)867
Other, net (1)10,6506,259
Stock-based compensation9,8957,811
Amortization of intangible assets attributable to acquisitions13,8506,263
Tax adjustments-7,525-2-4,602
Adjusted net income attributable to non-controlling interests-1,928-4-2,317
Adjusted net income attributable to Astrana Health, Inc.36,35320,502
Weighted average shares of common stock outstanding – diluted49,054,13548,850,666
Adjusted earnings per share - diluted0.740.42

Income Statement

Year Ending December 31, 2026 — Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands)

Year Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Net income54,00074,000
Interest expense51,00055,000
Provision for income taxes38,00044,000
Depreciation and amortization65,00065,000
EBITDA208,000238,000
Income from equity method investments-4,000-4,000
Other, net7,0007,000
Stock-based compensation39,00039,000
Adjusted EBITDA250,000280,000

Balance Sheet

March 31, 2026 — (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

March 31, 2026 – (Unaudited)December 31, 2025
Current assetsCash and cash equivalents478,383429,474
Current assetsReceivables, net (including amounts from related parties)467,395374,465

Cash Flow

Three Months Ended March 31, — (UNAUDITED) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31,Three Months Ended March 31, – 2025
Cash flows from operating activitiesNet income13,1316,221
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization15,4796,849
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of debt issuance cost1,134691
Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation9,8957,811
Adjustments to reconcile net income to net cash provided by operating activities:Non-cash lease expense2,0051,287
Adjustments to reconcile net income to net cash provided by operating activities:Deferred tax1,907-358
Adjustments to reconcile net income to net cash provided by operating activities:Change in fair value of contingent consideration liabilities5811,407
Adjustments to reconcile net income to net cash provided by operating activities:Other-2,564)729
Adjustments to reconcile net income to net cash provided by operating activities:Changes in operating assets and liabilities, net of business combinations26,488-8,010
Adjustments to reconcile net income to net cash provided by operating activities:Net cash provided by operating activities68,05616,627
Cash flows from investing activitiesPurchases of property and equipment-4,000)-3,070
Cash flows from investing activitiesOther1,156676
Cash flows from investing activitiesNet cash used in investing activities-2,844)-2,394
Cash flows from financing activitiesDividends paid-104)-5,455
Cash flows from financing activitiesBorrowings on debt412,000
Cash flows from financing activitiesRepayment of debt-11,967)-428,232
Cash flows from financing activitiesDeferred financing cost-17,241
Cash flows from financing activitiesTaxes paid from net share settlement of restricted stock-1,172)-4,052
Cash flows from financing activitiesRepurchase of treasury shares-2,906)
Cash flows from financing activitiesOther189-1,190
Cash flows from financing activitiesNet cash used in financing activities-15,960)-44,170
Cash flows from financing activitiesNet increase (decrease) in cash, cash equivalents, and restricted cash49,252-29,937
Cash flows from financing activitiesCash, cash equivalents, and restricted cash, beginning of period434,045289,101
Cash flows from financing activitiesCash, cash equivalents, and restricted cash, end of period483,297259,164
Supplemental disclosures of cash flow informationCash paid for income taxes-14,338
Supplemental disclosures of cash flow informationCash paid for interest14,7237,360
Supplemental disclosures of non-cash investing and financing activitiesRight-of-use assets obtained in exchange for operating lease liabilities3505,729

Cash Flow

Three Months Ended March 31, — Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net cash provided by operating activities68,05616,627
Purchases of property and equipment-4,000-3,070
Free cash flow64,05613,557

Cash Flow

Year Ending December 31, 2026 — Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)

Year Ending December 31, 2026 – Guidance Range – LowYear Ending December 31, 2026 – Guidance Range – High
Net cash provided by operating activities125,000145,000
Cash used in purchases of property and equipment-20,000-12,500
Free cash flow105,000132,500
Full release

See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.

Conference Call and Webcast Information:

Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, May 7,

2026), during which management will discuss the results of the first quarter ended March 31,

2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HHhCPjaF

An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website ( https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

Note About Consolidated Entities

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of income.

About Astrana Health, Inc.

Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

Today, Astrana supports more than 20,000 providers and approximately 1.55 million patients in value-based care arrangements through its affiliated provider... (truncated). Together,

Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance for the quarter ending June 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

FOR MORE INFORMATION, PLEASE CONTACT:

Carolyne Sohn, Investor Relations investors@astranahealth.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Astrana Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.